There was a significant reduction of MATE1-mRNA expression in patients who did not respond to imatinib and a strong correlation of MATE1-mRNA levels in total BM cells with the molecular response of CML patients. This evidence concerns the gene SLC47A1 and chronic myelogenous leukemia, BCR-ABL1 positive.